Open house Arzneimittelrabattverträge Tamsulosin und Dutasterid, ATC G04CA52
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tamsulosin und Dutasterid, ATC G04CA52
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
35 / 100
Risk factors
No minimum purchase or volume guarantee – revenue depends on actual prescriptions and uptake.
Open-house model is not subject to procurement law; remedies lie with social courts, not procurement chambers.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Supply of pharmaceutical products containing Tamsulosin and Dutasterid
- Conclusion of non-exclusive rebate agreements under § 130a Abs. 8 SGB V
Show full summary
This is an open-house model (not a public procurement procedure) by AOK Bayern for non-exclusive pharmaceutical rebate agreements on Tamsulosin and Dutasterid (ATC G04CA52). All interested pharmaceutical companies meeting eligibility criteria can conclude a contract. No estimated value provided. Duration from 01.06.2025 to 31.05.2027.
Risks
No minimum purchase or volume guarantee – revenue depends on actual prescriptions and uptake.
Open-house model is not subject to procurement law; remedies lie with social courts, not procurement chambers.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies eligible
Administrative
- Submission of signed declaration of reliability
- Submission of signed contract and annex listing the specific medicinal products
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Tamsulosin und Dutasterid, ATC G04CA52
Non-exclusive rebate agreements for pharmaceutical products with active ingredients Tamsulosin and Dutasterid. Contracts are open to all eligible pharmaceutical companies. No selection or award procedure.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 15 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 249174-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
35 / 100
Risk factors
No minimum purchase or volume guarantee – revenue depends on actual prescriptions and uptake.
Open-house model is not subject to procurement law; remedies lie with social courts, not procurement chambers.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications